GET SAME RESULTS BUT IN A SAFER WAY
Recurrent Angioedema and the Threat of AsphyxiationRecurrent angioedema may affect the skin or, less commonly, the tongue, gastrointestinal tract, and nebido free testosterone. Angioedema is a clinical sign that can be produced by a variety of diseases. Asphyxiation due to edematous obstruction of the upper airway is rare, but, for the affected patients, it is alternative to steroids for hives permanent risk. Hereditary angioedema due to C1 esterase inhibitor deficiency has been intensively studied, and nearly all steps in its pathogenesis are known, from the causative gene defect all the way to the clinical presentation of angioedema. Bradykinin is the main mediator in this pathway.
You have sent too many requests causing Linguee to block your computer
Recurrent angioedema may affect the skin or, less commonly, the tongue, gastrointestinal tract, and larynx. Angioedema is a clinical sign that can be produced by a variety of diseases. Asphyxiation due to edematous obstruction of the upper airway is rare, but, for the affected patients, it is a permanent risk. Hereditary angioedema due to C1 esterase inhibitor deficiency has been intensively studied, and nearly all steps in its pathogenesis are known, from the causative gene defect all the way to the clinical presentation of angioedema.
Bradykinin is the main mediator in this pathway. New treatment options icatibant; C1-inhibitor concentrate for self-administration and long-term treatment have helped patients considerably.
In recent years, a new type of hereditary angioedema has been described, resulting not from a lack of C1 inhibitor, but rather from mutations of coagulation factor XII or other, as yet unidentified genetic abnormalities.
There are major differences in the pharmacological treatment of the different diseases that cause angioedema. In an emergency, when severe upper airway obstruction can be life-threatening, immediate treatment is needed to keep the upper airway open.
In patients with recurrent angioedema, the diagnostic classification of the underlying disorder as a particular type of hereditary or acquired angioedema is a prerequisite for appropriate treatment. Angioedema also known as Quincke disease is the name given to edema lasting 1—7 days that recurs at irregular intervals. Target organs are the skin, tongue, glottis and larynx, gastrointestinal tract, and sometimes other soft organs. The clinical symptom referred to as angioedema forms part of a variety of disease entities Box 1 , Figure 1.
Cases of sudden asphyxiation are rare, but do occur every now and again 1. This review aims to draw attention to the various clinical features of recurrent angioedema and the practical steps for dealing with it, and to report the most recent developments in this field. The literature search was carried out on PubMed search terms: In this disease, almost all of the pathogenetic steps between the causative genetic defect and the clinical symptom of angioedema are now understood.
In addition to the treatments known hitherto, some new therapy options exist that intervene at various stages in the pathogenesis.
In Germany about patients have been diagnosed with this disease. About equal numbers of men and women are affected, so far as we know, but on average the disease is more severe in women 3. The gene that codes for the C1-esterase inhibitor C1-INH is located on the long arm of chromosome 11 in subregion q12—q New techniques for identifying mutations have shown more than mutants to date e1 , e2.
Patients with type 2 HAE also have one normal gene; the other one is abnormal and is expressed, leading to synthesis of dysfunctional C1-INH. C1-INH box 2 controls the spontaneous autoactivation of the first complement component C1 and activated C1.
A deficiency in functional C1-INH leads to activation of the initial phase of the complement system, and this results in a permanent reduction of plasma levels of C4. C1-INH is responsible for the inhibition of the greater part of plasma kallikrein and factor XIIa and is thus the most important regulator of activation of the kallikrein—kinin system. During acute attacks of HAE, kallikrein is insufficiently inhibited because of the deficiency in C1-INH, the kallikrein—kinin system contact system becomes activated, and at the end of the cascade there is an increased amount of bradykinin, the main mediator of increased vascular permeability and hence of the edema seen in HAE-C1-INH.
Interactions and potential interactions between the contact, complement, and fibrinolysis systems. Clinically, HAE-C1-INH is characterized by recurring swelling of the skin extremities, face, genitals , gastrointestinal attacks painful abdominal cramps, sometimes cardiovascular symptoms, vomiting, and diarrhea , and by edema of the larynx and other organs photo 3 — 5.
Death is most likely to occur in patients whose symptoms have not been diagnosed 1 , 5. HAE-C1-INH manifests itself most often in the first decade of life, frequently in the second, and in a few patients even later. Recurring attacks of edema follow, the frequency of which varies greatly from patient to patient. Some attacks are triggered by trauma, pressure, psychological stress situations, menstruation, ovulation, or infectious diseases. The tendency to edema attacks can be very greatly increased by ingestion of ACE inhibitors; these are contraindicated in patients with HAE.
ATII receptor blockers can also increase a tendency to edema attacks, although more rarely. In the same way, attacks may become more frequent in women receiving estrogen in contraceptives or as hormone replacement therapy e4.
The diagnosis of HAE-C1-INH is made on the basis of recurrent skin swellings, abdominal pain attacks, laryngeal edema, and a positive family history in combination with the relevant laboratory findings, i. Genetic testing is possible. Family testing, at least of close blood relatives, is required. Given the nature of the disease, for many patients medical therapy continues over many years, decades, or for their whole life.
The goals of treatment are:. Since sudden asphyxiation within hours can happen at any age and almost always occurs without warning, taking on the treatment of a patient with HAE-C1-INH is a great responsibility. It is essential to give the patient comprehensive and detailed knowledge of the symptoms, especially the initial symptoms, of laryngeal edema among other things: In the same way, other family members must be informed about the disease and the procedures that are needed.
Since all these procedures are important and time-consuming, it is advisable to make use of the experience of an HAE treatment center. Ideally the HAE patient will be looked after close to home by his or her primary care physician in collaboration with an HAE treatment center. The two largest treatment centers in Germany, which now have decades of experience in treating patients with HAE, are the Dermatology Clinic at the University of Mainz and the Pediatric Department at the University of Frankfurt.
Slight swellings of the hands and feet do not generally require treatment. Facial swellings in HAE should be treated, because quite often they are followed by laryngeal edema. Abdominal attacks, if mild, can be adequately treated with antispasmodic suppositories. However, most abdominal attacks are very painful and require treatment with C1-inhibitor concentrate or icatibant. Patients with HAE in the head area with edema of the pharynx or larynx represent an emergency, because of the imminent risk of asphyxiation, and should be admitted immediately for inpatient treatment.
Treatment for laryngeal edema depends on how far advanced the edema is. Patients with life-threatening dyspnea should be intubated without delay, using a fiberoptic bronchoscope if necessary, and in the most extreme case a coniotomy cricothyrotomy may be performed. The medical therapy of choice is treatment with a C1-INH concentrate or icatibant. Human C1-INH concentrate given intravenously has been proved a safe and highly effective treatment for acute attacks. It has been used in Germany for 30 years e5.
A series of observation studies have demonstrated its safety and effectiveness in treating laryngeal edema 6 , e6 , abdominal pain attacks 7 , and skin swellings 8 in HAE-C1-INH. A randomized, controlled study was published in 9. Another study, relating to the licensing of Berinert in the USA, was published recently For acute attacks, an early injection is recommended. Some patients now inject themselves with the preparation, or have it injected by a close relative, after appropriate instruction self-treatment at home 11 , e7.
Icatibant is a bradykinin B 2 receptor antagonist, similar in structure to bradykinin. One non-controlled 12 and two controlled, randomized studies licensing [phase III] studies with patients, publication in preparation have shown subcutaneously injected icatibant to be a safe and effective treatment for acute attacks of HAE-C1-INH.
The first subjective improvement of symptoms was noticed after an average of 48 minutes; the first clinical improvement was observed after a median of 2 to 2. Adverse effects include reactions at the injection site such as redness, wheal formation, and pain noted in more than 1 in 10 uses and a series of minor reactions including nausea, abdominal pain, and blocked nose noted in fewer than 1 in 10 but more than 1 in uses.
Icatibant has been licensed for use in the countries of the European Union since July However, FFP also contains proteins of the kallikrein—kinin system, and these could also lead to increased production of bradykinin, which could aggravate the attack.
Because of this and other drawbacks, treatment with FFP should if possible be avoided in Germany, where C1-INH concentrate and icatibant are available. Ecallantide is a synthetic kallikrein inhibitor that has been shown in several clinical studies to be highly effective in acute HAE attacks. It is now licensed for use in the USA.
A recombinant C1-INH has also been developed, obtained from the milk of transgenic rabbits. Corticosteroids, antihistamines, and epinephrine or epinephrine derivatives are not effective.
For long-term prophylaxis, androgen derivatives may be used, especially danazol, stanozolol, and oxandrolone. These androgens are highly effective. Regular follow-up visits are required to monitor for all unwanted effects In adults the efficacy of tranexamic acid is generally much lower than that of attenuated androgens. C1-INH concentrate can also be used for long-term prophylaxis 15 , 16 , e9.
This treatment should be reserved for particularly severe cases, however. The cause of death was almost always asphyxiation due to laryngeal edema. Today deaths are rare, but they do occur 1. In this form of angioedema, also hereditary type 3 HAE , those affected—almost always women—show normal plasma levels of C1-INH 17 , e Oral contraceptives, pregnancy, and hormone replacement therapy often play a particular role as triggering or aggravating factors.
Mutations of the factor XII gene have been demonstrated in some patients 18 , e Accordingly, C1q is usually decreased. In a significant proportion of these patients there is an underlying B-cell disorder, e. In some patients auto-antibodies against C1-INH are found e Several cases of death by asphyxiation following closure of the upper airways have been reported 22 , e The interval between the start of drug treatment and the appearance of the first angioedema can be months or several years, so that the causal connection between the angioedema and the triggering ACE inhibitors is sometimes recognized late.
ATII-receptor blockers can also trigger the same forms of angioedema, although more rarely. Aspirin and numerous other drugs are also known to be triggers. Angioedema can therefore also be symptom of this disease.
Angioedema in chronic recurrent urticaria usually responds well to corticosteroids and antihistamines. Recurrent idiopathic angioedema is the name given to cases of angioedema that cannot be identified as any of the other forms of angioedema: Knowledge about the pathogenesis and treatment of this form of angioedema is still very limited 23 , Angioedema, usually in the form of facial swelling, also occurs as a symptom of acute allergic or pseudo-allergic reaction 24 , In these cases it is usually, though not always, associated with urticaria or, more rarely, the symptoms of anaphylactic shock.
This form of angioedema also responds to corticosteroids and antihistamines. Usually it is a one-off occurrence; recurrences only occur on repeated exposure.
You have sent too many requests causing Linguee to block your computer
Home Remedies to Get Rid of Hives Fast and Naturally!. Management of cold urticaria ayurvedic treatment for papular urticaria,nodular urticaria pigmentosa chronic urticaria joint pain,urticaria solar tratamiento casero . 11 Jun Recurrent angioedema in patients with chronic urticaria . Icatibant is a bradykinin B2 receptor antagonist, similar in structure to bradykinin. . This form of angioedema also responds to corticosteroids and antihistamines.